Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate
Cancer/Radiothérapie · 2025
DOI: 10.1016/j.canrad.2025.104665 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer/Radiothérapie, 2025. Verfasst von Nassim Vibert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France. Electronic address: n.vibert@bordeaux.unicancer.fr. Hauptthemen laut MEDLINE: Gynecomastia, Prostatic Neoplasms, Androgen Antagonists, Androgen Receptor Antagonists. Die Arbeit nennt 57 Literaturangaben.
Abstract (Originalsprache)
This review aims to evaluate the incidence, clinical impact, and available therapeutic options for the management of gynecomastia induced by hormonal therapy, particularly in the era of androgen receptor pathway inhibitors, in patients with prostate cancer. We analysed data from clinical trials evaluating the incidence of gynecomastia under androgen receptor pathway inhibitors and the efficacy of both prophylactic and curative strategies, primarily tamoxifen and male breast radiotherapy, in patients receiving bicalutamide. Androgen receptor pathway inhibitors monotherapy is associated with high rates of gynecomastia (34 to 55 %), whereas combining androgen receptor pathway inhibitors with chemical castration significantly reduces this risk. Prophylactic tamoxifen significantly decreases gynecomastia incidence (down to 10 % versus 73 % without treatment) with good overall tolerance; prophylactic breast radiotherapy also shows efficacy. In the curative setting, tamoxifen appears more effective than radiotherapy, while surgery remains an invasive fallback option. However, extrapolating results obtained with bicalutamide to second-generation androgen receptor pathway inhibitors remains uncertain due to pharmacological and clinical differences. Gynecomastia could become a major complication of androgen receptor pathway inhibitors monotherapy. To date, tamoxifen and prophylactic breast radiotherapy are the most validated strategies, with the former appearing more effective. Further studies are needed to confirm their specific efficacy and safety in patients treated with androgen receptor pathway inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France. Electronic address: n.vibert@bordeaux.unicancer.fr.
- Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France; Université de Genève, rue du Général-Dufour 24, 1211 Genève, Suisse.
- Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France.
- Service de radiothérapie, Institut universitaire du cancer de Toulouse-Oncopole, institut Claudius-Regaud, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.
- Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France; Service de radiothérapie, Amethyst Radiotherapy Group, 65, avenue Foch, 92250 La Garenne-Colombes, France.
Zitieren
APA
Vibert, N., Achard, V., Pouvreau, P., Huck, C., Khalifa, J., & Sargos, P. (2025). Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2025.104665
Vancouver
Vibert N, Achard V, Pouvreau P, Huck C, Khalifa J, Sargos P. Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate. Cancer/Radiothérapie. 2025. doi:10.1016/j.canrad.2025.104665
BibTeX
@article{Vibert2025,
author = {Vibert, Nassim and Achard, Vérane and Pouvreau, Pierre and Huck, Constance and Khalifa, Jonathan and Sargos, Paul},
title = {Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate},
journal = {Cancer/Radiothérapie},
year = {2025},
doi = {10.1016/j.canrad.2025.104665}
}
EUVIMED